<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203112</url>
  </required_header>
  <id_info>
    <org_study_id>GA 9014</org_study_id>
    <nct_id>NCT00203112</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline</brief_title>
  <official_title>A Multi-Centered, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Assessing the Add-on Effect of Minocycline in Relapsing-Remitting Multiple Sclerosis (RR-MS) Subjects Treated With Glatiramer Acetate (GA).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the add-on effect of oral minocycline in subjects treated with daily&#xD;
      injection of Copaxone. Copaxone and minocycline are thought to have differential modes of&#xD;
      actions that may complement each other in treating MS symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the add-on treatment effect of oral minocycline in subjects treated with daily injection of GA as reflected by number of MRI T1 Gd-enhancing lesions in T1-weighted images.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability and safety</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Relapse Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Glatiramer Acetate injection with oral minocycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glatiramer Acetate 20mg with oral minocycline 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glatiramer Acetate with placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glatiramer acetate injection 20mg with oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glatiramer acetate with minocycline</intervention_name>
    <description>Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg</description>
    <arm_group_label>Glatiramer Acetate injection with oral minocycline</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer acetate with placebo</intervention_name>
    <description>Subcutaneous injection glatiramer acetate 20mg, with oral placebo</description>
    <arm_group_label>Glatiramer Acetate with placebo</arm_group_label>
    <other_name>Copaxone®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically definite MS as defined by Poser et al. (Ann. Neurol. 1983) with disease&#xD;
             duration (from onset) of at least 6 months.&#xD;
&#xD;
          2. Subjects must have a relapsing-remitting disease course.&#xD;
&#xD;
          3. Subjects must have had at least 1 documented relapse within the last year prior to&#xD;
             study entry.&#xD;
&#xD;
          4. Subjects must have at least 1 and not more than 15 gadolinium (Gd)-enhancing lesions&#xD;
             on the screening MRI scan.&#xD;
&#xD;
          5. Subjects must be relapse-free and not have taken corticosteroids (IV, IM and/or PO)&#xD;
             within the 30 days prior to the screening visit.&#xD;
&#xD;
          6. Subjects may be male or female. Women of child- bearing potential must use a&#xD;
             contraceptive method deemed reliable by the investigator.&#xD;
&#xD;
          7. Subjects must be between the ages of 18 and 50 years inclusive.&#xD;
&#xD;
          8. Subjects must be ambulatory, with a Kurtzke EDSS score of between 0 and 5.0 inclusive.&#xD;
&#xD;
          9. Subjects must be willing and able to give written informed consent prior to entering&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous use of injectable glatiramer acetate.&#xD;
&#xD;
          2. Previous use of cladribine.&#xD;
&#xD;
          3. Previous use of immunosuppressive agents in the last 6 months.&#xD;
&#xD;
          4. Use of experimental or investigational drugs, including I.V. immunoglobulin and&#xD;
             statins, within 6 months prior to study entry.&#xD;
&#xD;
          5. Use of interferon agents or minocycline within 4 months prior to the screening visit.&#xD;
&#xD;
          6. Chronic corticosteroid (IV, IM and/or PO) treatment (more than 30 consecutive days) in&#xD;
             the 6 months prior to study entry.&#xD;
&#xD;
          7. Previous total body irradiation or total lymphoid irradiation (TLI).&#xD;
&#xD;
          8. Pregnancy or breast feeding.&#xD;
&#xD;
          9. Subjects who experience a relapse between the screening (month -1) and baseline (month&#xD;
             0) visits.&#xD;
&#xD;
         10. Significant medical or psychiatric condition that affects the subject's ability to&#xD;
             give informed consent, or to complete the study, or any condition which the&#xD;
             investigator feels may interfere with participation in the study (e.g. alcohol or drug&#xD;
             abuse).&#xD;
&#xD;
         11. A known history of sensitivity to mannitol.&#xD;
&#xD;
         12. Contraindication to or known history of sensitivity to tetracyclines.&#xD;
&#xD;
         13. A known history of sensitivity to gadolinium.&#xD;
&#xD;
         14. Inability to successfully undergo MRI scanning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Godin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience Canada</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <results_reference>
    <citation>Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW; GA/minocycline study investigators. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler. 2009 Oct;15(10):1183-94. doi: 10.1177/1352458509106779. Epub 2009 Sep 23.</citation>
    <PMID>19776092</PMID>
  </results_reference>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 11, 2011</last_update_submitted>
  <last_update_submitted_qc>April 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jean-Louis Strill, MD</name_title>
    <organization>Teva Canada Innovation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

